Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Julia A. Newton-Bishop
Based on 2 articles published since 2010
(Why 2 articles?)
||||

Between 2010 and 2020, Julia A. Newton-Bishop wrote the following 2 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Article Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. 2019

Taylor, Nicholas J / Mitra, Nandita / Qian, Lu / Avril, Marie-Françoise / Bishop, D Timothy / Bressac-de Paillerets, Brigitte / Bruno, William / Calista, Donato / Cuellar, Francisco / Cust, Anne E / Demenais, Florence / Elder, David E / Gerdes, Anne-Marie / Ghiorzo, Paola / Goldstein, Alisa M / Grazziotin, Thais C / Gruis, Nelleke A / Hansson, Johan / Harland, Mark / Hayward, Nicholas K / Hocevar, Marko / Höiom, Veronica / Holland, Elizabeth A / Ingvar, Christian / Landi, Maria Teresa / Landman, Gilles / Larre-Borges, Alejandra / Mann, Graham J / Nagore, Eduardo / Olsson, Håkan / Palmer, Jane M / Perić, Barbara / Pjanova, Dace / Pritchard, Antonia L / Puig, Susana / Schmid, Helen / van der Stoep, Nienke / Tucker, Margaret A / Wadt, Karin A W / Yang, Xiaohong R / Newton-Bishop, Julia A / Kanetsky, Peter A / Anonymous3411133. ·Department of Epidemiology and Biostatistics, Texas A&M University, College Station, Texas. · Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania. · Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. · Assistance Publique-Hôpitaux de Paris, Hôpital Cochin et Université Paris Descartes, Paris, France. · Section of Epidemiology and Biostatistics, Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, United Kingdom. · Gustave Roussy, Université Paris-Saclay, Département de Biopathologie and Institut National de la Santé et de la Recherche Médicale U1186, Villejuif, France. · Department of Internal Medicine and Medical Specialties, University of Genoa and Istituto de Ricovero e Cura a Carattere Scientifico AOU San Martino-IST, Genoa, Italy. · Dermatology Unit, Maurizio Bufalini Hospital, Cesena, Italy. · Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Institut de Investigacions Biomediques August Pi Sunyer, Universitat de Barcelona, Barcelona, Spain. · Sydney School of Public Health, The University of Sydney, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. · Institut National de la Santé et de la Recherche Médicale UMR-946, Genetic Variation and Human Disease Unit, Université Paris Diderot, Paris, France. · Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. · Department of Clinical Genetics, University Hospital of Copenhagen, Copenhagen, Denmark. · Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. · Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil. · Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands. · Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. · QIMR Berghofer Medical Research Institute, Herston, Australia. · Institute of Oncology Ljubljana, Zaloska, Ljubljana, Slovenia. · Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Westmead Institute for Medical Research, University of Sydney, Sydney, Australia. · Department of Clinical Sciences, Lund University Hospital Lund, Sweden; Department of Surgery, Lund University Hospital, Lund, Sweden. · Department of Pathology, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. · Unidad de Lesiones Pigmentadas, Cátedra de Dermatología, Hospital de Clínicas, Universidad de la República, Montevideo, Uruguay. · Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain. · Latvian Biomedical Research and Study Centre, Riga, Latvia. · Melanoma Unit, Dermatology Department, Hospital Clinic Barcelona, Institut de Investigacions Biomediques August Pi Sunyer, Universitat de Barcelona, Barcelona, Spain; Centro de Investigacion Biomedica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Barcelona, Spain. · Department of Clinical Genetics, Leiden University Medical Center Leiden, the Netherlands. · Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Electronic address: peter.kanetsky@moffitt.org. ·J Am Acad Dermatol · Pubmed #30731170.

ABSTRACT: BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved. METHODS: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics. RESULTS: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance. CONCLUSION: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.

2 Article Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. 2017

Fang, Jun / Jia, Jinping / Makowski, Matthew / Xu, Mai / Wang, Zhaoming / Zhang, Tongwu / Hoskins, Jason W / Choi, Jiyeon / Han, Younghun / Zhang, Mingfeng / Thomas, Janelle / Kovacs, Michael / Collins, Irene / Dzyadyk, Marta / Thompson, Abbey / O'Neill, Maura / Das, Sudipto / Lan, Qi / Koster, Roelof / Anonymous1181133 / Anonymous1191133 / Anonymous1201133 / Stolzenberg-Solomon, Rachael S / Kraft, Peter / Wolpin, Brian M / Jansen, Pascal W T C / Olson, Sara / McGlynn, Katherine A / Kanetsky, Peter A / Chatterjee, Nilanjan / Barrett, Jennifer H / Dunning, Alison M / Taylor, John C / Newton-Bishop, Julia A / Bishop, D Timothy / Andresson, Thorkell / Petersen, Gloria M / Amos, Christopher I / Iles, Mark M / Nathanson, Katherine L / Landi, Maria Teresa / Vermeulen, Michiel / Brown, Kevin M / Amundadottir, Laufey T. ·Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. · Department of Molecular Biology, Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen 6500 HB, The Netherlands. · Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. · Cancer Genomics Research Laboratory, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, USA. · Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire 03756, USA. · Protein Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, USA. · Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA. · Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115, USA. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA. · Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA. · Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York City, New York 10065, USA. · Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA. · Section of Epidemiology and Biostatistics, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK. · Department of Oncology, University of Cambridge, Cambridge CB2 0XZ, UK. · Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA. · Translational Medicine and Human Genetics, Department of Medicine and Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. ·Nat Commun · Pubmed #28447668.

ABSTRACT: Genome wide association studies (GWAS) have mapped multiple independent cancer susceptibility loci to chr5p15.33. Here, we show that fine-mapping of pancreatic and testicular cancer GWAS within one of these loci (Region 2 in CLPTM1L) focuses the signal to nine highly correlated SNPs. Of these, rs36115365-C associated with increased pancreatic and testicular but decreased lung cancer and melanoma risk, and exhibited preferred protein-binding and enhanced regulatory activity. Transcriptional gene silencing of this regulatory element repressed TERT expression in an allele-specific manner. Proteomic analysis identifies allele-preferred binding of Zinc finger protein 148 (ZNF148) to rs36115365-C, further supported by binding of purified recombinant ZNF148. Knockdown of ZNF148 results in reduced TERT expression, telomerase activity and telomere length. Our results indicate that the association with chr5p15.33-Region 2 may be explained by rs36115365, a variant influencing TERT expression via ZNF148 in a manner consistent with elevated TERT in carriers of the C allele.